Business
Partnering for global impact
Driving the adoption of CATUVAB® and ABCR-Technology worldwide through strategic collaborations and investments.
Launch Strategy
LBC is the MedTech company which developed CATUVAB®, the first device to remove cancer cells and cancer stem cells of 14 major tumor indications from salvaged blood during cancer surgeries
Home Market
Dedicated sales force to deeply understand customer needs.
Licencing
Markets where additional studies might be needed (e.g., Japan, China).
Distribution
Timely market access.
Trusted by leading investors
Our journey is supported by leading investors who share our vision of improving patient outcomes in cancer surgeries and beyond.
“I am pleased to support LBC in realizing their vision of autologous blood management for tumor patients and to pave the way from product development to market launch.”
– Sebastian Burian
“PermaDoc is excited to support this important project which aims to improve the life of cancer patients.”
– Andreas Billand
“Improving the quality of life of patients is a guiding principle of our investment decisions. We are proud to support Lindis Blood Care in bringing their exciting new product to market.”
– Dr. Klaus Hilleke-Daniel